The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Abstract
The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3′-azido-3′-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4 + HeLa cells. Fifty percent inhibitory dose (ID 50 ) values of 18 isolates from untreated individuals ranged between 0.01 μ M and 0.05 μ M . In contrast, most isolates from patients who had received zidovudine for 6 months or more exhibited decreased sensitivity characterized by changes in ID 50 or ID 95 values (or both), with isolates from several patients (5/15) showing 100-fold increases in ID 50 . The latter isolates were also insensitive to 3′-azido-2′,3′-dideoxyuridine; however, the isolates were still sensitive to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-2′,3′-didehydrothymidine, or phosphonoformate. It cannot be determined from this small sample of patients whether development of a less sensitive virus phenotype results in clinical resistance. Appearance of such variants was not associated with a consistent increase in viral p24 concentrations in patient plasma and did not herald any sudden deterioration in clinical status. More extensive studies are required to determine the clinical significance. Thus, it would be premature to alter any treatment protocols for HIV-infected individuals at present.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a clinical trial, its dramatic short-term effects in delaying the death of AIDS patients (109) led to its rapid approval for use, although the virus rebounded after a few months due to the appearance of mutations in RT that render it AZT resistant (110).”
From The Discovery of Reverse Transcriptase (2016) · cites this paper as [110]
Citations
Cites
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
Self-citationThe Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170402 · Cited by 1,199
Self-citationInfection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay
Harada, S., Koyanagi, Y., & Yamamoto, N. (1985) · Science · doi:10.1126/science.2992081 · Cited by 857
Schmitt, F. A., Bigley, J. W., McKinnis, R., Logue, P. E., Evans, R. W., Drucker, J. L., & The AZT Collaborative Working Group* (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192404 · Cited by 396
Klecker, R. W., Collins, J. M., Yarchoan, R., Thomas, R., Jenkins, J. F., Broder, S., & Myers, C. E. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.49 · Cited by 381
Site-specific mutagenesis of AIDS virus reverse transcriptase
Larder, B. A., Purifoy, D. J. M., Powell, K. L., & Darby, G. (1987) · Nature · doi:10.1038/327716a0 · Cited by 312
Self-citationDevelopment of a sensitive quantitative focal assay for human immunodeficiency virus infectivity
Chesebro, B., & Wehrly, K. (1988) · Journal of Virology · doi:10.1128/jvi.62.10.3779-3788.1988 · Cited by 304
Field, H. J., & Darby, G. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.2.209 · Cited by 242
Self-citationISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPY
Burns, W., Santos, G., Saral, R., Laskin, O., Lietman, P., Mclaren, C., & Barry, D. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91620-8 · Cited by 240
Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance
Darby, G., Field, H. J., & Salisbury, S. A. (1981) · Nature · doi:10.1038/289081a0 · Cited by 204
Self-citation
Cited by
Items 201–300 of 1,000
Transmission of Human Immunodeficiency Virus Type 1 Resistant to Nevirapine and Zidovudine
Imrie, A. A., Beveridge, A., Genn, W., Vizzard, J., Cooper, D. A., & the Sydney Primary HIV Infection St Group (1997) · The Journal of Infectious Diseases · doi:10.1086/516487 · Cited by 127
Zhou, P., Goldstein, S. C., Devadas, K., Tewari, D., & Notkins, A. L. (1997) · Nature Medicine · doi:10.1038/nm0697-659 · Cited by 127
Comparative Pharmacokinetics of Antiviral Nucleoside Analogues
Morse, G. D., Shelton, M. J., & OʼDonnell, A. M. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324020-00002 · Cited by 126
Meek, T. D. (1992) · Journal of enzyme inhibition · doi:10.3109/14756369209041357 · Cited by 126
Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication
Maeda, K., Das, D., Kobayakawa, T., Tamamura, H., & Takeuchi, H. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190712204603 · Cited by 125
Faulds, D. M., & Brogden, R. N. (1992) · Drugs · doi:10.2165/00003495-199244010-00008 · Cited by 125
Nguyen, J. T., Hoopes, J. D., Smee, D. F., Prichard, M. N., Driebe, E. M., Engelthaler, D. M., Le, M. H., Keim, P., Spence, R. P., & Went, G. T. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00476-09 · Cited by 124
Perno, C. F., Cozzi‐Lepri, A., Balotta, C., Forbici, F., Violin, M., Bertoli, A., Facchi, G., Pezzotti, P., Cadeo, G., Tositti, G., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/323604 · Cited by 124
HIV-1: The infective process in vivo
McCune, J. M. (1991) · Cell · doi:10.1016/0092-8674(91)90644-e · Cited by 124
Baba, M., Shigeta, S., Yuasa, S., Takashima, H., Sekiya, K., Ubasawa, M., TANAKA, H., MIYASAKA, T., Walker, R. T., & Clercq, E. D. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.688 · Cited by 123
Guillemont, J., Pasquier, E., Palandjian, P., Vernier, D., Gaurrand, S., Lewi, P. J., Heeres, J., de Jonge, M. R., Koymans, L. M. H., Daeyaert, F. F. D., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040838n · Cited by 122
Chemokines and receptors in HIV encephalitis.
Gómez-Cano, M., Rubio, A., Puig, T., Pérez-Olmeda, M., Ruiz, L., Soriano, V., Pineda, J. A., Zamora, L., Xaus, N., Clotet, B., et al. (1998) · PubMed · Cited by 122
Eo, S. K., Kim, Y.-S., Lee, C., & Han, S.-S. (1999) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(99)00067-7 · Cited by 121
Nef Neutralizes the Ability of Exosomes from CD4+ T Cells to Act as Decoys during HIV-1 Infection
de Carvalho, J. V., de Castro, R. O., da Silva, E. Z. M., Silveira, P. P., da Silva-Januário, M. E., Arruda, E., Jamur, M. C., Oliver, C., Aguiar, R. S., & daSilva, L. L. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113691 · Cited by 120
Deval, J., Selmi, B., Boretto, J., Egloff, M. P., Guerreiro, C., Sarfati, S. R., & Canard, B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206725200 · Cited by 120
Johnson, P. R., Hamm, T. E., Goldstein, S. C., Kitov, S., & Hirsch, V. M. (1991) · Virology · doi:10.1016/0042-6822(91)90769-8 · Cited by 120
Buckheit, R. W., Fliakas-Boltz, V., Decker, W. D., Roberson, J. L., Pyle, C., White, E. L., Bowdon, B. J., McMahon, J. B., Boyd, M. R., Bader, J. P., et al. (1994) · Antiviral Research · doi:10.1016/0166-3542(94)90092-2 · Cited by 119
Anti-Human Immunodeficiency Virus Drug Combination Strategies
Vandamme, A.-M., Vaerenbergh, K. V., & Clercq, E. D. (1998) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029800900301 · Cited by 119
Pauza, C. D., Galindo, J., & Richman, D. D. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.4.1035 · Cited by 119
Self-citationHarrigan, P. R., Kinghorn, I., Bloor, S., Kemp, S. D., Nájera, I., Kohli, A., & Larder, B. A. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.5930-5934.1996 · Cited by 119
Self-citationKoup, R. A., Merluzzi, V. J., Hargrave, K. D., Adams, J., Grözinger, K. G., Eclmer, R. J., & Sullivan, J. L. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/163.5.966 · Cited by 118
Yeh, P., Landais, D., Lemaitre, M. M., Maury, I., Crenne, J.-Y., Becquart, J., Murry‐Brelier, A., Boucher, F., Montay, G., & Fleer, R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1904 · Cited by 118
Human Immunodeficiency Virus Type 1 Protease Inhibitors
McDonald, C., & Kuritzkes, D. R. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440300037003 · Cited by 118
Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)
Sluis-Cremer, N., Arion, D., & Parniak*, M. A. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000626 · Cited by 117
Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1
Anderson, R. M., Gupta, S., & May, R. M. (1991) · Nature · doi:10.1038/350356a0 · Cited by 117
RNA virus evolution and the control of viral disease
Domingo, E. (1989) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-9146-2_5 · Cited by 117
Antiviral Portrait Series: 4. Polysuifates as Inhibitors of HIV and Other Enveloped Viruses
Witvrouw, M., Desmyter, J., & Clercq, E. D. (1994) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029400500601 · Cited by 116
Pluda, J. M., Cooley, T. P., Montaner, J. S. G., Shay, L. E., Reinhalter, N. E., Warthan, S. N., Ruedy, J., Hirst, H. M., Vicary, C., QUINN, J., et al. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1438 · Cited by 116
Liu, X., Wan, Z.-J., Shi, L., & Lü, X. (2010) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2010.08.044 · Cited by 115
Lea, A. P., & Faulds, D. M. (1996) · Drugs · doi:10.2165/00003495-199651050-00009 · Cited by 115
Notka, F., MEIER, G., & Wagner, R. (2003) · Antiviral Research · doi:10.1016/s0166-3542(02)00213-9 · Cited by 114
Hooker, D. J., Tachedjian, G., Solomon, A. E., Gurusinghe, A. D., Land, S., Birch, C. J., Anderson, J. L., Roy, B. M., Arnold, E., & Deacon, N. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8010-8018.1996 · Cited by 114
Kerr, S. G., & Anderson, K. S. (1997) · Biochemistry · doi:10.1021/bi9713862 · Cited by 114
Richman, D. D., Guatelli, J. C., Grimes, J. M., Tsiatis, A. A., & Gingeras, T. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.6.1075 · Cited by 114
Self-citationInsights Into HIV Chemotherapy*
Schinazi, R. F., Mead, J. R., & Feorino, P. M. (1992) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1992.8.963 · Cited by 114
Kumar, V., Sardana, S., & Madan, A. K. (2004) · Journal of Molecular Modeling · doi:10.1007/s00894-004-0215-8 · Cited by 113
van Opijnen, T., Jeeninga, R. E., Boerlijst, M. C., Pollakis, G., Zetterberg, V., Salminen, M. O., & Berkhout, B. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3675-3683.2004 · Cited by 113
HIV-1 sensitivity to zidovudine and clinical outcome in children
Tudor‐Williams, G., Clair, M. H. S., McKinney, R. E., Maha, M., Walter, E., Santacroce, S., Mintz, M., O'Donnell, K., Rudoll, T., & Vavro, C. L. (1992) · The Lancet · doi:10.1016/0140-6736(92)90140-x · Cited by 112
Sardana, V. V., Emini, E. A., Gotlib, L., Graham, D. J., Lineberger, D. W., Long, W. J., Schlabach, A. J., Wolfgang, J., & Condra, J. H. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)37074-7 · Cited by 112
Dose–response curve slope is a missing dimension in the analysis of HIV-1 drug resistance
Sampah, M. E., Shen, L., Jilek, B. L., & Siliciano, R. F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018360108 · Cited by 111
Montefiori, D. C., & Zhou, J. (1991) · Antiviral Research · doi:10.1016/0166-3542(91)90037-r · Cited by 110
HIV-1 reverse transcriptase inhibitors
Safadi, Y. E., Vivet‐Boudou, V., & Marquet, R. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-0919-7 · Cited by 110
Miller, V., & Larder, B. A. (2001) · Antiviral Therapy · doi:10.1177/135965350100603s03 · Cited by 110
Self-citationMerrill, D. P., Moonis, M., Chou, T., & Hirsch, M. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.2.355 · Cited by 109
Anti-HIV Activityin Vitroof MGN-3, an Activated Arabinoxylane from Rice Bran
Ghoneum, M. H. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.8047 · Cited by 108
Highly Active Antiretroviral Therapies Are Effective against HIV-1 Cell-to-Cell Transmission
Agosto, L. M., Zhong, P., Munro, J. B., & Mothes, W. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003982 · Cited by 107
Vanhems, P., Allard, R., Cooper, D. A., Perrin, L., Vizzard, J., Hirschel, B. J., Loes, S. K., Carr, A. D., & Lambert, J. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.5.965 · Cited by 107
Nucleoside and nucleotide inhibitors of HIV-1 replication
Vivet‐Boudou, V., Didierjean, J., Isel, C., & Marquet, R. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5367-x · Cited by 106
Métifiot, M., Marchand, C., & Pommier, Y. G. (2013) · Advances in pharmacology · doi:10.1016/b978-0-12-405880-4.00003-2 · Cited by 104
Antiretroviral therapy in Africa
Stevens, W., Kaye, S., & Corrah, T. (2004) · BMJ · doi:10.1136/bmj.328.7434.280 · Cited by 104
Cannon, J. S., Hamzeh, F. M., Moore, S. M., Nicholas, J., & Ambinder, R. F. (1999) · Journal of Virology · doi:10.1128/jvi.73.6.4786-4793.1999 · Cited by 104
Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient
Knox, K. K., Drobyski, W. R., & Carrigan, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92965-5 · Cited by 104
Decreased In Vitro Susceptibility to Zidovudine of HIV Isolates Obtained from Patients with AIDS
Land, S., Treloar, G., McPhee, D. A., Birch, C. J., Doherty, R. R., Cooper, D. A., & Gust, I. D. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/161.2.326 · Cited by 104
Rompay, K. K. A. V., Otsyula, M., Marthas, M. L., Miller, C. J., McChesney, M. B., & Pedersen, N. C. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.125 · Cited by 103
Sharma, P., & Crumpacker, C. S. (1997) · Journal of Virology · doi:10.1128/jvi.71.11.8846-8851.1997 · Cited by 103
Managing Resistance to Anti-HIV Drugs: An Important Consideration for Effective Disease Management
Vandamme, A., Laethem, K. V., & Clercq, E. D. (1999) · Drugs · doi:10.2165/00003495-199957030-00006 · Cited by 103
Zhou, W., Gumina, G., Chong, Y., Wang, J., Schinazi, R. F., & Chu, C. K. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040027j · Cited by 102
Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr
Planelles, V., Bachelerie, F., Jowett, J. B. M., Haislip, A. M., Xie, Y., Banooni, P., Masuda, T., & Chen, I. S. (1995) · Journal of Virology · doi:10.1128/jvi.69.9.5883-5889.1995 · Cited by 102
Caliendo, A. M., Savara, A. V., An, D., Devore, K. M., Kaplan, J. C., & D’Aquila, R. T. (1996) · Journal of Virology · doi:10.1128/jvi.70.4.2146-2153.1996 · Cited by 102
Schooley, R. T., Ramirez-Ronda, C. H., Lange, J. M. A., Cooper, D. A., Lavelle, J. P., Lefkowitz, L. B., Moore, M. L., Larder, B. A., Clair, M. S., Mulder, J. W., et al. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.6.1354 · Cited by 102
Self-citationKellam, P., Boucher, C. A., Tijnagel, J. M. G. H., & Larder, B. A. (1994) · Journal of General Virology · doi:10.1099/0022-1317-75-2-341 · Cited by 102
Self-citationNucleoside Analogs: Similarities and Differences
Sommadossi, J. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/16.supplement_1.s7 · Cited by 102
Pharmacokinetics of Stavudine in Patients with AIDS or AIDS-Related Complex
Dudley, M. N., Graham, K. K., Kaul, S., Geletko, S. M., Dunkle, L. M., & Mayer, K. H. (1992) · The Journal of Infectious Diseases · doi:10.1093/infdis/166.3.480 · Cited by 101
Role of p38 mitogen-activated protein kinase in HIV type 1 production in vitro
Shapiro, L., Heidenreich, K. A., Meintzer, M. K., & Dinarello, C. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7422 · Cited by 100
Nasr, M., Litterst, C. L., & McGowan, J. J. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90030-b · Cited by 100
Frenkel, L. M., Wagner, L. E., Demeter, L. M., Dewhurst, S., Coombs, R. W., Murante, B. L., & Reichman, R. C. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.5.1321 · Cited by 100
(±)-Dioxolane-T ((±)-1-[(2β,4β)-2-(hydroxymethyl)-4-dioxolanyl]thymine)
Norbeck, D. W., Spanton, S. G., Broder, S. E., & Mitsuya, H. (1989) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)93868-7 · Cited by 99
Incidence and impact of resistance against approved antiretroviral drugs
Pillay, D., Taylor, S. R., & Richman, D. D. (2000) · Reviews in Medical Virology · doi:10.1002/1099-1654(200007/08)10:4<231::aid-rmv290>3.0.co;2-p · Cited by 99
Self-citationThe Latest Progress in the Synthesis of Carbocyclic Nucleosides
Zhu, X. (2000) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770008035015 · Cited by 98
Bozzette, S. A., McCutchan, J. A., Spector, S. A., Wright, B. C., & Richman, D. D. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/168.6.1374 · Cited by 98
Self-citationSrinivas, R. V., & Fridland, A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.6.1484 · Cited by 97
Failed prophylactic zidovudine after needlestick injury
Looke, D. F. M., & Grove, D. I. (1990) · The Lancet · doi:10.1016/0140-6736(90)91343-9 · Cited by 97
Julias, J. G., & Pathak, V. K. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.7941-7949.1998 · Cited by 96
de Jong, M. D., Veenstra, J., Stilianakis, N. I., Schuurman, R., Lange, J. M. A., de Boer, R. J., & Boucher, C. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5501 · Cited by 96
Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants
Domingo, E., Menéndez‐Arias, L., Quiñones‐Mateu, M. E., Holguín, Á., Gutiérrez‐Rivas, M., Martínez, M. Á., Quer, J., Novella, I. S., & Holland, J. J. (1997) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8861-5_4 · Cited by 95
Moog, C., Wick, A. E., Ber, P. L., Kirn, A., & Aubertin, A.-M. (1994) · Antiviral Research · doi:10.1016/0166-3542(94)90075-2 · Cited by 95
Yoshida, T., Yasuda, Y., Mimura, T., Kaneko, Y., Nakashima, H., Yamamoto, N., & Uryu, T. (1995) · Carbohydrate Research · doi:10.1016/0008-6215(95)00186-w · Cited by 94
Anti-HIV (human immunodeficiency virus) activity of sulfated paramylon
Koizumi, N., Sakagami, H., Utsumi, A., FUJINAGA, S., Takeda, M., Asano, K., Sugawara, I., Ichikawa, S., Kondo, H., Mori, S., et al. (1993) · Antiviral Research · doi:10.1016/0166-3542(93)90063-o · Cited by 94
Hachiya, A., Matsuoka, S., Tanaka, M., Takahashi, Y., Ida, S., Gatanaga, H., Hirabayashi, Y., Kojima, A., Tatsumi, M., & Oka, S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.495-501.2001 · Cited by 94
Antiviral therapy: current concepts and practices
Bean, B. (1992) · Clinical Microbiology Reviews · doi:10.1128/cmr.5.2.146 · Cited by 94
Byers, V. S., Levin, A. S., MALVINO, A., Waites, L. A., Robins, R. A., & Baldwin, R. W. (1994) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1994.10.413 · Cited by 92
IκB-α, the NF-κB Inhibitory Subunit, Interacts with ANT, the Mitochondrial ATP/ADP Translocator
Bottero, V., Rossi, F., Samson, M., Mari, M., Hofman, P. M., & Peyron, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005850200 · Cited by 92
Stein, C., Pal, R., DeVico, A. L., Hoke, G., Mumbauer, S. W., Kinstler, O. B., Sarngadharan, M. G., & Letsinger, R. L. (1991) · Biochemistry · doi:10.1021/bi00223a020 · Cited by 92
Central nervous system complications of HIV infection.
Luetkemeyer, A. F., Havlir, D. V., & Currier, J. S. (2011) · Europe PMC (PubMed Central) · Cited by 91
HIV Genetic Diversity and Drug Resistance
Santos, A. F., & Soares, M. A. (2010) · Viruses · doi:10.3390/v2020503 · Cited by 91
Pizzo, P. A., BUTLER, K. M., Balis, F. M., Brouwers, E., Hawkins, M. E., Eddy, J., Einloth, M., Falloon, J., Husson, R. N., Jarosinski, P. F., et al. (1990) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83348-7 · Cited by 91
Considerations in choice of a clinical endpoint for AIDS clinical trials
Neaton, J. D., Wentworth, D. N., Rhame, F. S., Hogan, C., Abrams, D. I., & Deyton, L. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131919 · Cited by 90
Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance.
Nyce, J. W., Leonard, S., CANUPP, D., Schulz, S., & Wong, S. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.7.2960 · Cited by 90
Yarchoan, R., Lietzau, J., Nguyen, B., Brawley, O. W., Pluda, J. M., Saville, M. W., Wyvill, K. M., Steinberg, S. M., Agbaria, R., Mitsuya, H., et al. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.1.9 · Cited by 90
Buckheit, R. W., Hollingshead, M. G., Decker, J. M., White, E. L., McMahon, J. B., Allen, L. B., Ross, L. J., Decker, W. D., Westbrook, L., Shannon, W. M., et al. (1993) · Antiviral Research · doi:10.1016/0166-3542(93)90031-d · Cited by 90
High Diversity of HIV-1 Subtype F Strains in Central Africa
Triques, K., Bourgeois, A., Saragosti, S., Vidal, N., Mpoudi‐Ngolé, E., Nzilambi, N., Apetrei, C., Ekwalanga, M., Delaporte, É., & Peeters, M. (1999) · Virology · doi:10.1006/viro.1999.9720 · Cited by 89
Deeks, S. G., Martin, J. N., Sinclair, E., Harris, J., Neilands, T. B., Maecker, H. T., Hagos, E., Wrin, T., Petropoulos, C. J., Bredt, B. M., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/380098 · Cited by 89
Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine
Remington, K. M., Chesebro, B. W., Wehrly, K., Pedersen, N. C., & North, T. W. (1991) · Journal of Virology · doi:10.1128/jvi.65.1.308-312.1991 · Cited by 89
Törnevik, Y., Ullman, B., Balzarini, J. M., Wahrén, B., & Eriksson, S. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00453-s · Cited by 89
Ray, A. S., Murakami, E., Basavapathruni, A., Vaccaro, J. A., Ulrich, D. L., Chu, C. K., Schinazi, R. F., & Anderson, K. S. (2003) · Biochemistry · doi:10.1021/bi034435l · Cited by 88
Mansuri, M. M., Hitchcock, M. J. M., Buroker, R. A., Bregman, C. L., Ghazzouli, I., Desiderio, J. V., Starrett, J. E., Sterzycki, R., & Martin, J. C. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.4.637 · Cited by 88
Gu, Z., Quan, Y., Zhou, L., Arts, E. J., & Wainberg, M. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.52.31046 · Cited by 88
Mohri, H., Singh, M. K., Ching, W., & Ho, D. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.1.25 · Cited by 88
Transmission and Prevalence of HIV Resistance among Treatment-Naive Subjects
Little, S. J. (2000) · Antiviral Therapy · doi:10.1177/135965350000500111 · Cited by 87
HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy
Loveday, C., Kaye, S., Semple, M. G., Ayliffe, V., Tedder, R. S., Tenant‐Flowers, M., & Weller, I. V. D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92963-0 · Cited by 87
Metadata
- Authors
- Larder, B. A., Darby, G., & Richman, D. D.
- Affiliations
- Wellcome Trust (GB)
- University of California San Diego (US)
- ORCID
- Richman, Douglas D.
- Venue
- Science
- Published
- 1989-03-31
- Volume
- 243
- Issue
- 4899
- Pages
- 1731-1734
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2086462809
- Cited by
- 1,559
- References
- 22
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 3 · 2023: 10 · 2022: 12 · 2021: 8 · 2020: 9 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 16 · 2015: 10 · 2014: 21 · 2013: 13 · 2012: 16
- FWCI
- 157.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HB-6-7019)
- National Institute of Allergy and Infectious Diseases (AI-62548, AI-52578)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- HIV drug resistance, zidovudine resistance, AIDS, AIDS-related complex, antiretroviral therapy, 2',3'-dideoxycytidine, phosphonoformate
- MeSH terms
- Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Drug Resistance, HeLa Cells, HIV, Humans, Microbial Sensitivity Tests, Phosphonoacetic Acid, Viral Plaque Assay, Retroviridae Proteins, Virus Replication, Zidovudine, Dideoxynucleosides, Zalcitabine, HIV Core Protein p24, Foscarnet, Reverse Transcriptase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.